CTI BIOPHARMA

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2014-01-01

Employees: -

Market Cap: -

Website: http://www.ctibiopharma.com/

Clinical Trials

Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects

Phase 1

Completed

Conditions: Drug Interactions

Interventions: Drug: CYP450 Cocktail and Transporter Substrates with Pacritinib
Drug: Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
Drug: Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib

First Posted Date: 2022-12-20

Last Posted Date: 2024-10-17

Lead Sponsor: CTI BioPharma

Target Recruit Count: 60

Registration Number: NCT05657613

Locations: 🇺🇸
Site 1, Austin, Texas, United States

Study to Evaluate the Safety, Tolerability, and PK of Pacritinib

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: oral dose of 200 mg pacritinib twice daily (BID)

First Posted Date: 2022-09-23

Last Posted Date: 2024-10-21

Lead Sponsor: CTI BioPharma

Target Recruit Count: 29

Registration Number: NCT05552183

Locations: 🇺🇸
Site 2, Orlando, Florida, United States
🇺🇸
Site 1, San Antonio, Texas, United States

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Phase 2

Completed

Conditions: Primary Myelofibrosis
Post- Essential Thrombocythemia Myelofibrosis
Post-Polycythemia Vera Myelofibrosis

Interventions: Drug: Pacritinib

First Posted Date: 2021-05-12

Last Posted Date: 2022-06-01

Lead Sponsor: CTI BioPharma

Target Recruit Count: 165

Registration Number: NCT04884191

Locations: 🇺🇸
University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
City of Hope, Duarte, California, United States

and more 57 locations

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

Phase 2

Terminated

Conditions: COVID-19
COVID
COVID19

Interventions: Drug: Placebo
Drug: Pacritinib

First Posted Date: 2020-05-27

Last Posted Date: 2024-06-05

Lead Sponsor: CTI BioPharma

Target Recruit Count: 200

Registration Number: NCT04404361

Locations: 🇺🇸
St. Jude Hospital Yorba Linda dba St. Joseph Heritage Healthcare, Orange, California, United States
🇺🇸
Overlook Medical Center, Morristown, New Jersey, United States
🇺🇸
Ascension St. Vincent's Riverside Hospital, Jacksonville, Florida, United States

and more 18 locations

To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

First Posted Date: 2016-07-06

Last Posted Date: 2023-09-15

Lead Sponsor: CTI BioPharma

Target Recruit Count: 28

Registration Number: NCT02823171

Locations: 🇺🇸
Covance Clinical Research Unit Inc., Evansville, Indiana, United States

PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects

Phase 1

Completed

Conditions: Myelofibrosis

Interventions: Drug: Pacritinib

First Posted Date: 2016-06-21

Last Posted Date: 2018-10-22

Lead Sponsor: CTI BioPharma

Target Recruit Count: 40

Registration Number: NCT02807077

Locations: 🇲🇩
Republican Clinical Hospital, Chisinau, Moldova, Republic of
🇷🇴
Carol Davila Nephrology Hospital Bucharest, Bucharest, Romania
🇩🇪
APEX GmbH, Munich, Germany

Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Pacritinib
Drug: Rifampin
Drug: Pacritinib and Rifampin

First Posted Date: 2016-06-21

Last Posted Date: 2023-09-15

Lead Sponsor: CTI BioPharma

Target Recruit Count: 18

Registration Number: NCT02807116

Locations: 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States

To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

First Posted Date: 2016-06-21

Last Posted Date: 2023-09-15

Lead Sponsor: CTI BioPharma

Target Recruit Count: 42

Registration Number: NCT02807207

Locations: 🇺🇸
Covance Clinical Research Unit Inc., Evansville, Indiana, United States

Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: (Treatment A)
Drug: (Treatment B)

First Posted Date: 2016-06-21

Last Posted Date: 2023-09-15

Lead Sponsor: CTI BioPharma

Target Recruit Count: 12

Registration Number: NCT02808455

Locations: 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States

To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects

Phase 1

Completed

Conditions: Drug Interaction Study

Interventions: Drug: Pacritinib
Drug: Clarithromycin
Drug: Pacritinib and Clarithromycin

First Posted Date: 2016-06-21

Last Posted Date: 2020-01-29

Lead Sponsor: CTI BioPharma

Target Recruit Count: 20

Registration Number: NCT02807051

Locations: 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy